E. Leonard

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma

T. Carey, Jingyi Zhai, J. Brenner, 2019, Molecular Pharmacology.

Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.

N. Michmerhuizen, J. Brenner, E. Leonard, 2016, Otorhinolaryngology-head and neck surgery.

Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy

M. Prince, J. Brenner, N. Michmerhuizen, 2020, Journal of Neuro-Oncology.

Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model.

E. Bellile, N. Michmerhuizen, J. Brenner, 2022, Oral oncology.